Historical lly News Stories
Lilly Surge: $3.5B Plant & Record 2026 Outlook Now
Eli Lilly (LLY) gained momentum this week after announcing a $3.5B Lehigh Valley manufacturing complex, issuing a bullish $80–$83B 2026 revenue guide driven by tirzepatide sales, and benefiting from regulatory moves that reduced low-cost competition. These concrete developments underpin near-term growth and investor confidence in LLY within the S&P 500.
Lilly Acquires Orna; GLP-1 Sales Drive Q4 Jump Now
Eli Lilly’s $2.4B buy of Orna Therapeutics and a blockbuster GLP‑1 quarter — driven by Mounjaro and Zepbound — underscore the company’s shift into cell and genetic therapies while sustaining outsized revenue growth. Strong Q4 results, bullish 2026 guidance, and an advancing oral GLP‑1 program combine with industry price competition to shape LLY’s near-term outlook.